BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29718366)

  • 1. Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
    Stadlbauer A; Zimmermann M; Doerfler A; Oberndorfer S; Buchfelder M; Coras R; Kitzwögerer M; Roessler K
    Neuro Oncol; 2018 Oct; 20(11):1536-1546. PubMed ID: 29718366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans.
    Stadlbauer A; Oberndorfer S; Zimmermann M; Renner B; Buchfelder M; Heinz G; Doerfler A; Kleindienst A; Roessler K
    J Cereb Blood Flow Metab; 2020 Mar; 40(3):528-538. PubMed ID: 30732550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.
    Stadlbauer A; Zimmermann M; Bennani-Baiti B; Helbich TH; Baltzer P; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
    Mol Imaging Biol; 2019 Aug; 21(4):758-770. PubMed ID: 30478507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular architecture mapping for early detection of glioblastoma recurrence.
    Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
    Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energy Metabolism in
    van Noorden CJF; Hira VVV; van Dijck AJ; Novak M; Breznik B; Molenaar RJ
    Cells; 2021 Mar; 10(3):. PubMed ID: 33810170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization.
    Wang W; Li T; Cheng Y; Li F; Qi S; Mao M; Wu J; Liu Q; Zhang X; Li X; Zhang L; Qi H; Yang L; Yang K; He Z; Ding S; Qin Z; Yang Y; Yang X; Luo C; Guo Y; Wang C; Liu X; Zhou L; Liu Y; Kong W; Miao J; Ye S; Luo M; An L; Wang L; Che L; Niu Q; Ma Q; Zhang X; Zhang Z; Hu R; Feng H; Ping YF; Bian XW; Shi Y
    Cancer Cell; 2024 May; 42(5):815-832.e12. PubMed ID: 38640932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
    Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
    Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
    Khan I; Waqas M; Shamim MS
    J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
    Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
    J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effect of vascularity between long- and short-term survivors with IDH1/2 wild-type glioblastoma.
    Álvarez-Torres MDM; Fuster-García E; Reynés G; Juan-Albarracín J; Chelebian E; Oleaga L; Pineda J; Auger C; Rovira A; Emblem KE; Filice S; Mollà-Olmos E; García-Gómez JM
    NMR Biomed; 2021 Apr; 34(4):e4462. PubMed ID: 33470039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma.
    Chen L; Lin ZX; Lin GS; Zhou CF; Chen YP; Wang XF; Zheng ZQ
    Hum Pathol; 2015 Jan; 46(1):120-8. PubMed ID: 25455996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.